Developer docs
API playgroundTry for free, no card

Search company profiles

BioScience Managers Limited

Full company profile

uuid0009j1i

Namestring
BioScience Managers Limited
Legal namestring
BioScience Managers Pty Ltd
Company typeenum
Private
Founded yearint
2003
Descriptiontext

BioScience Managers Limited (legal entity BioScience Managers Pty Ltd, formerly IB Managers) is a private, Melbourne-headquartered international healthcare investment firm founded in 2003 by Jeremy Curnock Cook, former head of the Biosciences Unit at Rothschild Asset Management. The firm operates as a specialist life sciences funds manager, investing across three pillars — Genomic Medicine, Paediatrics, and Digital Technologies in Healthcare — into private and public companies with biotechnology, medical device, and digital health product profiles globally. Its portfolio spans more than a dozen named companies including Acrux, Adherium, Calcimedica, Cynata Therapeutics, Saluda Medical, and PKG/Global Kinetics Corporation.

The firm has raised and managed at least five distinct investment vehicles: IB Australian Bioscience Fund I (2008, A$42M), Asia Pacific Healthcare Fund II (2013, A$56M), Ventures Fund I and the Translation Fund (2017), and Ventures Fund II (2023), drawing capital primarily from Australian superannuation funds, family offices, university endowments, and the Australian Federal Government. It operates as a Corporate Authorised Representative of Phillip Asset Management Limited within the PhillipCapital Group (parent AUM >US$35B, presence in 15 countries) and holds FCA-regulated status in the UK through Sturgeon Ventures LLP.

Revenue derives from management fees and performance fees (carried interest) on funds under management, with disclosed annualised net IRR exceeding 20%. The firm operates from offices in Melbourne, Perth, Singapore, London, Istanbul, Boston, Los Angeles, and Vancouver, with a senior team combining scientific, clinical, and commercialisation backgrounds. Notable exits include Peplin (acquired by Leo Pharma for US$287.5M), Arana Therapeutics (merged with Cephalon), and Biota Holdings (merged to form Vaxart).

Short descriptiontext

BioScience Managers is a private, Melbourne-headquartered healthcare-focused funds manager founded in 2003 that invests across life sciences, medical devices, and digital health globally, raising capital from superannuation funds, family offices, and government LPs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare investment management, life sciences venture capital, biotechnology fund management, medical device investment, institutional fund management
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Healthcare and Life Sciences Fund Management
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Funds Management Fees
TypeSubscription Recurring
Description

BioScience Managers generates revenue through management fees and performance fees (carried interest) from managing healthcare-focused investment funds. The firm manages multiple funds including Australian Bioscience Fund I, Asia Pacific Healthcare Fund II, Ventures Fund I, Translation Fund, and Ventures Fund II.

biosciencemanagers.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioScience Managers is a specialist healthcare-focused fund management firm that raises capital from institutional investors and deploys it into private and public life sciences, biotechnology, medical device, and digital health companies through multiple closed-end investment funds. The firm provides development and commercialisation capital combined with active portfolio management support, leveraging a global network of advisers and industry experts to source, invest in, and exit healthcare innovation deals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 20%+ annualised net IRR
+1 more record
Product overview1 text field

BioScience Managers is an international healthcare investment firm that finances and supports innovative science and technology. The company operates as a fund management platform offering multiple investment funds: IB Australian Bioscience Fund I (2008), Asia Pacific Healthcare Fund II (2013), BioScience Managers Ventures Fund I, Translation Fund (2017), and Ventures Fund II (2023). The company also maintains a portfolio of healthcare companies across life sciences, medical devices, and digital health technologies. The funds target both private and public healthcare companies with clear technological and market advantages, focusing on genomic medicine, paediatrics, and digital technologies as core investment pillars.

Product and service5 records
1IB Australian Bioscience Fund I
CategoryFund / Investment Product
Description

BioScience Managers' first closed-end healthcare investment fund, raised in 2008 from superannuation funds, university endowment funds, and family offices, focused on Australian-based biotechnology innovation with global healthcare market translation.

2Asia Pacific Healthcare Fund II
CategoryFund / Investment Product
Description

Second BioScience Managers fund, launched in 2013 with A$56M raised from superannuation and family offices, focused on Asia Pacific healthcare investment opportunities.

3BioScience Managers Ventures Fund I
CategoryFund / Investment Product
Description

Venture fund raised in 2017 from superannuation and family offices, targeting venture-stage healthcare investment opportunities.

4BioScience Managers Translation Fund
CategoryFund / Investment Product
Description

Translation-focused fund raised in 2017 from superannuation and family offices, targeting early-stage healthcare innovation translation.

5BioScience Managers Ventures Fund II
CategoryFund / Investment Product
Description

Fifth and most recent BioScience Managers fund, launched in 2023 and open to new investors, focused on venture investments in healthcare innovation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

Affiliated with AusBioTech, Australia's national peak body for the biotechnology sector, supporting industry connections and visibility.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Affiliated with the Australian Investment Council, supporting investment industry connections.

3UK BioIndustry Association (UK BIA)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Affiliated with UK BIA, the UK's national trade association for the bioscience sector.

biosciencemanagers.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partnership with ANDHealth, a non-profit organisation supporting digital health company commercialisation in Australia.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global healthcare-dedicated investment firm across venture, growth, and public equity strategies. Most directly comparable healthcare-specialist investment manager to BioScience Managers in mandate and fund structure.

TypeDirect peer
Description

US-based healthcare and life sciences focused investment manager with crossover and venture funds. Comparable in being a specialist healthcare-only investment platform serving institutional LPs.

TypeDirect peer
Description

US-based venture firm focused exclusively on early-stage life sciences and physical sciences companies. Directly comparable in its life sciences-only mandate and active portfolio support model.

TypeDirect peer
Description

Dedicated healthcare investment firm with both growth and venture strategies. Comparable in offering multiple fund vintages to LPs and being a healthcare-only specialist.

TypeDirect peer
Description

Australian life sciences venture and growth manager, also backed by the Australian Federal Government. Most direct Australian-based peer given shared geography, LP base, and life sciences focus.

TypeDirect peer
Description

Australian venture and growth firm with dedicated healthcare and biotech funds. Comparable in being an APAC-based healthcare specialist raising from institutional LPs.

TypeDirect peer
Description

US healthcare-dedicated investment firm founded by Dennis Purcell (an Independent Director of BioScience Managers). Comparable mandate and stage focus.

TypeDirect peer
Description

European life sciences venture and growth specialist with multiple fund vintages. Comparable in being a healthcare-only specialist serving institutional LPs across geographies.

9Tekla Capital Management
TypeDirect peer
Description

US-based investment manager focused exclusively on healthcare and life sciences public and private equities. Comparable in running dedicated healthcare funds for institutional investors.

TypeRegional player
Description

Australian deep-tech and life sciences venture investor. Regional peer with overlapping biotech mandate but broader technology focus than BSM's pure healthcare strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment24 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioScience Managers Limited

Healthcare and Life Sciences Fund Managementbiosciencemanagers.com

BioScience Managers is a private, Melbourne-headquartered healthcare-focused funds manager founded in 2003 that invests across life sciences, medical devices, and digital health globally, raising capital from superannuation funds, family offices, and government LPs.

What BioScience Managers Limited does

BioScience Managers Limited (legal entity BioScience Managers Pty Ltd, formerly IB Managers) is a private, Melbourne-headquartered international healthcare investment firm founded in 2003 by Jeremy Curnock Cook, former head of the Biosciences Unit at Rothschild Asset Management. The firm operates as a specialist life sciences funds manager, investing across three pillars — Genomic Medicine, Paediatrics, and Digital Technologies in Healthcare — into private and public companies with biotechnology, medical device, and digital health product profiles globally. Its portfolio spans more than a dozen named companies including Acrux, Adherium, Calcimedica, Cynata Therapeutics, Saluda Medical, and PKG/Global Kinetics Corporation.

The firm has raised and managed at least five distinct investment vehicles: IB Australian Bioscience Fund I (2008, A$42M), Asia Pacific Healthcare Fund II (2013, A$56M), Ventures Fund I and the Translation Fund (2017), and Ventures Fund II (2023), drawing capital primarily from Australian superannuation funds, family offices, university endowments, and the Australian Federal Government. It operates as a Corporate Authorised Representative of Phillip Asset Management Limited within the PhillipCapital Group (parent AUM >US$35B, presence in 15 countries) and holds FCA-regulated status in the UK through Sturgeon Ventures LLP.

Revenue derives from management fees and performance fees (carried interest) on funds under management, with disclosed annualised net IRR exceeding 20%. The firm operates from offices in Melbourne, Perth, Singapore, London, Istanbul, Boston, Los Angeles, and Vancouver, with a senior team combining scientific, clinical, and commercialisation backgrounds. Notable exits include Peplin (acquired by Leo Pharma for US$287.5M), Arana Therapeutics (merged with Cephalon), and Biota Holdings (merged to form Vaxart).

BioScience Managers Limited firmographics

Firmographics
Name
BioScience Managers Limited
Legal name
BioScience Managers Pty Ltd
Website
https://biosciencemanagers.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
1–10 employees
Short description
BioScience Managers is a private, Melbourne-headquartered healthcare-focused funds manager founded in 2003 that invests across life sciences, medical devices, and digital health globally, raising capital from superannuation funds, family offices, and government LPs.
Ownership category
akta.pro rank

BioScience Managers Limited industry classification

Industry
Product category
Healthcare and Life Sciences Fund Management
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Healthcare investment management
  • Life sciences venture capital
  • Biotechnology fund management
  • Medical device investment
  • Institutional fund management

Where BioScience Managers Limited is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices8 records

Markets served

BioScience Managers Limited business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Funds Management Fees: BioScience Managers generates revenue through management fees and performance fees (carried interest) from managing healthcare-focused investment funds. The firm manages multiple funds including Australian Bioscience Fund I, Asia Pacific Healthcare Fund II, Ventures Fund I, Translation Fund, and Ventures Fund II.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

BioScience Managers Limited product offering

Product offering

Core offering

BioScience Managers is a specialist healthcare-focused fund management firm that raises capital from institutional investors and deploys it into private and public life sciences, biotechnology, medical device, and digital health companies through multiple closed-end investment funds. The firm provides development and commercialisation capital combined with active portfolio management support, leveraging a global network of advisers and industry experts to source, invest in, and exit healthcare innovation deals.

Product overview

BioScience Managers is an international healthcare investment firm that finances and supports innovative science and technology. The company operates as a fund management platform offering multiple investment funds: IB Australian Bioscience Fund I (2008), Asia Pacific Healthcare Fund II (2013), BioScience Managers Ventures Fund I, Translation Fund (2017), and Ventures Fund II (2023). The company also maintains a portfolio of healthcare companies across life sciences, medical devices, and digital health technologies. The funds target both private and public healthcare companies with clear technological and market advantages, focusing on genomic medicine, paediatrics, and digital technologies as core investment pillars.

Differentiator

Problem solved

Functional benefit

Products and services

  • IB Australian Bioscience Fund I BioScience Managers' first closed-end healthcare investment fund, raised in 2008 from superannuation funds, university endowment funds, and family offices, focused on Australian-based biotechnology innovation with global healthcare market translation.
  • Asia Pacific Healthcare Fund II Second BioScience Managers fund, launched in 2013 with A$56M raised from superannuation and family offices, focused on Asia Pacific healthcare investment opportunities.
  • BioScience Managers Ventures Fund I Venture fund raised in 2017 from superannuation and family offices, targeting venture-stage healthcare investment opportunities.
  • BioScience Managers Translation Fund Translation-focused fund raised in 2017 from superannuation and family offices, targeting early-stage healthcare innovation translation.
  • BioScience Managers Ventures Fund II Fifth and most recent BioScience Managers fund, launched in 2023 and open to new investors, focused on venture investments in healthcare innovation.

Quantifiable outcome

  • 20%+ annualised net IRR
  • +1 more outcomes

Companies that use BioScience Managers Limited

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles2 records

BioScience Managers Limited technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioScience Managers Limited partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor.

  • AusBioTechminorGTM or Marketing PartnerAffiliated with AusBioTech, Australia's national peak body for the biotechnology sector, supporting industry connections and visibility.
  • Australian Investment Council (AIC)minorGTM or Marketing PartnerAffiliated with the Australian Investment Council, supporting investment industry connections.
  • UK BioIndustry Association (UK BIA)minorGTM or Marketing PartnerAffiliated with UK BIA, the UK's national trade association for the bioscience sector.
  • ANDHealthminorGTM or Marketing PartnerPartnership with ANDHealth, a non-profit organisation supporting digital health company commercialisation in Australia.

Scale indicators7 records

Recent moves12 records

Expansion highlights5 records

BioScience Managers Limited competitors and assessment

Company assessment

Direct peers

  • OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equity strategies. Most directly comparable healthcare-specialist investment manager to BioScience Managers in mandate and fund structure.
  • RA Capital Management: US-based healthcare and life sciences focused investment manager with crossover and venture funds. Comparable in being a specialist healthcare-only investment platform serving institutional LPs.
  • ARCH Venture Partners: US-based venture firm focused exclusively on early-stage life sciences and physical sciences companies. Directly comparable in its life sciences-only mandate and active portfolio support model.
  • Frazier Healthcare Partners: Dedicated healthcare investment firm with both growth and venture strategies. Comparable in offering multiple fund vintages to LPs and being a healthcare-only specialist.
  • Brandon Capital Partners: Australian life sciences venture and growth manager, also backed by the Australian Federal Government. Most direct Australian-based peer given shared geography, LP base, and life sciences focus.
  • OneVentures: Australian venture and growth firm with dedicated healthcare and biotech funds. Comparable in being an APAC-based healthcare specialist raising from institutional LPs.
  • Aisling Capital: US healthcare-dedicated investment firm founded by Dennis Purcell (an Independent Director of BioScience Managers). Comparable mandate and stage focus.
  • Sofinnova Partners: European life sciences venture and growth specialist with multiple fund vintages. Comparable in being a healthcare-only specialist serving institutional LPs across geographies.
  • Tekla Capital Management: US-based investment manager focused exclusively on healthcare and life sciences public and private equities. Comparable in running dedicated healthcare funds for institutional investors.

Regional players

  • CM Capital Investments: Australian deep-tech and life sciences venture investor. Regional peer with overlapping biotech mandate but broader technology focus than BSM's pure healthcare strategy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

BioScience Managers Limited social profiles

Digital presence

BioScience Managers Limited financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioScience Managers Limited leadership team

Management profile

Number of profiles

Profiles15 records

BioScience Managers Limited funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioScience Managers Limited M&A and investment

M&A and investment

M&A1 record

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioScience Managers Limited

What does BioScience Managers Limited do?

BioScience Managers is a specialist healthcare-focused fund management firm that raises capital from institutional investors and deploys it into private and public life sciences, biotechnology, medical device, and digital health companies through multiple closed-end investment funds. The firm provides development and commercialisation capital combined with active portfolio management support, leveraging a global network of advisers and industry experts to source, invest in, and exit healthcare innovation deals.

Is BioScience Managers Limited a public or private company?

BioScience Managers Limited is a private company. It is classified as corporate owned and is currently operating.

When was BioScience Managers Limited founded?

BioScience Managers Limited was founded in 2003. It employs 1 to 10 people.

Where is BioScience Managers Limited based?

BioScience Managers Limited is headquartered in Melbourne, Australia, in the Oceania region.

How does BioScience Managers Limited make money?

One revenue line is on record: funds Management Fees.

Who are BioScience Managers Limited's main competitors?

Direct peers on record are OrbiMed Advisors, RA Capital Management, ARCH Venture Partners, Frazier Healthcare Partners, Brandon Capital Partners, OneVentures, Aisling Capital, Sofinnova Partners and Tekla Capital Management. CM Capital Investments is listed as a regional player.

Does BioScience Managers Limited have an API?

No public API is recorded for BioScience Managers Limited.

What industry is BioScience Managers Limited in?

BioScience Managers Limited's product category is Healthcare and Life Sciences Fund Management. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital HealthBioScience Managers, an international healthcare investment firm headquartered in Melbourne, Australia with offices in London, announced the appointment of David Atkins as Managing Partner to work alongside founder Jeremy Curnock Cook and drive future growth in digital health across new and existing geographies. Atkins brings over 22 years of experience including senior leadership roles at Johnson & Johnson, Danaher, and Medicover, and recently led Congenica, a digital health scale-up in Cambridge, through major financing rounds. The firm manages approximately AUD$250 million across a portfolio of 20+ investments in life sciences, digital health, and techbio companies.GlobeNewswireCynata Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development PipelineCynata Therapeutics raised $15m in a placement led by $10m from BioScience Managers, with a 1-for-15 entitlement offer to shareholders. The funds will expand its clinical pipeline into idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers, targeting a combined market over $20bn annually.PR NewswireBioScience Managers Invests in Canary Medical's Proprietary 'Smart' Implant TechnologyBioScience Managers invested in Canary Medical's CHIRP implantable reporting processor, a smart medical device for remote patient monitoring. The investment was part of a syndicate led by Quark Venture and GF Securities. The company plans to develop a smart artificial knee implant and later vascular implants.VC News DailyNexus6 Breathes in New CapitalBioScience Managers Pty Ltd announced a NZ$3m investment in New Zealand asthma technology company Nexus6, as part of a larger funding round totaling NZ$4.6m, with additional support from existing shareholders including K1W1. The capital will fund international expansion of Nexus6's Smartinhaler product range, which remotely monitors patient adherence to asthma treatment protocols. The investment represents BioScience Managers' second investment from its AU$55m Asia Pacific Healthcare Fund II.